Venn diagram.

It may indicate combo inhibition of both proteasomes and Bcl-2 is a recipe for disease. The FDA has halted patient enrollment on clinical trials investigating the novel Bcl-2 inhibitor venetoclax after recent safety data reported double the rate of death with it versus placebo when added to bortezomib for multiple myeloma. | AbbVie 2019